Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases.
about
Update on treatment of lysosomal storage diseasesHematopoietic stem cell transplantation for Morquio A syndrome.Young-onset dementiaCell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidosesGrowth patterns and the use of growth hormone in the mucopolysaccharidoses.Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.Newborn screening for hunter disease: a small-scale feasibility studyMucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantationLong-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA.Disease specific therapies in leukodystrophies and leukoencephalopathies.Glycosaminoglycan storage disorders: a reviewNeural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy.A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I.Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VIDiagnostic and treatment strategies in mucopolysaccharidosis VI.Current and emerging therapies for the lysosomal storage disorders.Neurodegeneration and cell replacement.Juvenile metachromatic leukodystrophy: understanding the disease and implications for nursing care.Expanding the role of umbilical cord blood transplantation.Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders.The function of sphingolipids in the nervous system: lessons learnt from mouse models of specific sphingolipid activator protein deficiencies.Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy.Emerging trends in transplantation of inherited metabolic diseases.Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observationsLysosomal storage disorders in the newborn.Inherited metabolic disorders involving the eye: a clinico-biochemical perspective.Umbilical cord blood transplantation for non-malignant diseases.Stem cells in genetic myelin disorders.Emerging drugs for lysosomal storage diseases.Fetal gene therapy: recent advances and current challenges.Treatment options for lysosomal storage disorders: developing insights.Emerging treatments for pediatric leukodystrophies.Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.Transplantation in inborn errors of metabolism: current considerations and future perspectives.Hematopoietic stem cell transplantation for inborn errors of metabolism: A report from the Research Committee on Transplantation for Inborn Errors of Metabolism of the Japanese Ministry of Health, Labour and Welfare and the Working Group of the JapaIntranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells
P2860
Q24595945-D4941426-30AA-4CEF-9AFC-B76218C048ADQ30809579-EE36C43C-0EC9-47D9-8CFA-8CB2F93FFA04Q33660849-32D419D4-0776-4C0D-A4D9-EFEB848C94A1Q33692991-CE7D7CE9-4AE5-4473-A9C0-3221BFDA9550Q33918468-6246B118-094C-40F7-A8E5-85D36F21220BQ34078512-BB50B8A9-86A7-476F-9213-0FD61E6D9309Q34325171-8412C956-9635-4142-8956-3473AF807B6CQ34422346-0377005B-3CBB-4F74-9591-C84CE0A24EC0Q34562817-044F180C-CFD8-4100-9CEC-46F8DB9A4D36Q34763337-66226730-B6DC-46B0-946D-228A0E173C0FQ34938821-DCD58838-2B82-459D-864C-F5540FC92484Q35328494-2BFD609E-2202-47DE-BF8C-ADA10DB374FEQ35367599-53D157E4-BC06-4DAD-BB83-8E8B6391CD65Q35590505-AFE9E88C-AD18-47AB-A493-6C16A0863CC7Q35665076-63C5A9D8-9909-4742-A1A1-2D6D8FF44552Q36009130-A7EAAD0B-567E-4C26-82C3-810AD1E2B9A4Q36253221-08028ED7-9631-4FCA-96B8-99964895D0D1Q36302871-8D58AB24-F2AC-40BE-8F7E-1E0AF4E2E55EQ36748869-DED0FBCA-98C9-43A6-BAB7-7BEED44BFF88Q36749075-CB617F0F-9DDB-406A-A05D-6A4684C3F5ECQ36759585-B40AA095-E2BF-4977-82C0-27A2FD7679A3Q36797112-C057252C-8503-41F5-8D65-592BA18C48C5Q36994535-36C05F19-72CC-425C-A72F-9F4B326294A2Q37019501-FB8D0B4A-0E78-44AC-B2F3-7D82BDB88877Q37051044-971D4ADB-AA86-412B-B637-1D7EA6D98A4CQ37265581-CDA49E5C-B6E0-4D19-90AC-52AB4570163BQ37401176-9C9CB535-8722-4499-816A-21BC6B7255B0Q37607099-FC8B063F-CA7F-4F74-8ABE-A519F72BA512Q37607972-042CC002-26A9-4BD1-BEC9-64E6E42E9490Q37747349-27547F95-E16D-4A8E-BF40-B924F5E4B8ECQ37765901-D632518E-9974-4615-857F-C91606A5353CQ37881971-92488212-E918-46E5-B9F5-6C0BD2E12E5EQ38046227-AAA8A48A-3BB1-4710-AA35-E0896762ABCBQ38506539-48B39571-99A8-4962-BD21-DB3AEB4AB7A6Q38695475-D907050D-003F-434D-B65A-1005092F6050Q38703339-AD4A29D5-1B18-47B3-990E-C942CF000EFDQ39151620-04A5D01D-E6FB-4A75-A6DB-FE22575437C4Q40066114-06430219-73C8-4FFA-B92A-11449A0F4096Q40219437-9CEF8674-3FE0-4BF5-A53C-D6785B24CCFDQ41948861-A41B386E-5162-4746-AF17-48F1F8CC7F36
P2860
Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@ast
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@en
type
label
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@ast
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@en
prefLabel
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@ast
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@en
P1476
Allogeneic stem cell transplan ...... eroxisomal metabolic diseases.
@en
P2093
William Krivit
P2888
P304
P356
10.1007/S00281-004-0166-2
P577
2004-09-25T00:00:00Z